Applied Therapeutics, Inc.
APLTDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Diabetic Cardiomyopathies
1 drug in this indication
Classic Galactosemia
1 drug in this indication
Hereditary Neuropathy Caused by SORD Deficiency
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Applied Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Applied Therapeutics, Inc.'s (APLT) pipeline across Phase 3. Its lead program is AT-001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Applied Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Applied Therapeutics, Inc. (APLT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track APLT biotech catalysts?→
Add APLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Applied Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.